---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T23:22:02.393352'
end_time: '2026-01-11T23:31:59.794135'
duration_seconds: 597.4
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: STAT3
  gene_symbol: STAT3
  uniprot_accession: P40763
  protein_description: 'RecName: Full=Signal transducer and activator of transcription
    3 {ECO:0000305}; AltName: Full=Acute-phase response factor {ECO:0000303|PubMed:7512451};'
  gene_info: Name=STAT3 {ECO:0000303|PubMed:9630560, ECO:0000312|HGNC:HGNC:11364};
    Synonyms=APRF {ECO:0000303|PubMed:7512451};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the transcription factor STAT family.
  protein_domains: p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf.
    (IPR036860); STAT. (IPR001217); STAT3_SH2. (IPR035855)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P40763
- **Protein Description:** RecName: Full=Signal transducer and activator of transcription 3 {ECO:0000305}; AltName: Full=Acute-phase response factor {ECO:0000303|PubMed:7512451};
- **Gene Information:** Name=STAT3 {ECO:0000303|PubMed:9630560, ECO:0000312|HGNC:HGNC:11364}; Synonyms=APRF {ECO:0000303|PubMed:7512451};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the transcription factor STAT family.
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf. (IPR036860); STAT. (IPR001217); STAT3_SH2. (IPR035855)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "STAT3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'STAT3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **STAT3** (gene ID: STAT3, UniProt: P40763) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P40763
- **Protein Description:** RecName: Full=Signal transducer and activator of transcription 3 {ECO:0000305}; AltName: Full=Acute-phase response factor {ECO:0000303|PubMed:7512451};
- **Gene Information:** Name=STAT3 {ECO:0000303|PubMed:9630560, ECO:0000312|HGNC:HGNC:11364}; Synonyms=APRF {ECO:0000303|PubMed:7512451};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the transcription factor STAT family.
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf. (IPR036860); STAT. (IPR001217); STAT3_SH2. (IPR035855)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "STAT3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'STAT3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **STAT3** (gene ID: STAT3, UniProt: P40763) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status (concise): Identity/domain verification completed; recent sources (2023–2024) collected; canonical and non-canonical mechanisms consolidated; clinical applications and degraders summarized; evidence table prepared; proceeding with final report.

Comprehensive research report: Human STAT3 (UniProt P40763)

Target verification and scope
- Gene/protein: STAT3 (Signal transducer and activator of transcription 3), UniProt P40763, Homo sapiens. Member of the STAT transcription factor family; domain architecture includes N-terminal domain (ND), coiled-coil domain (CCD), DNA-binding domain (DBD), linker domain, SH2 domain, and C-terminal transactivation domain (TAD), consistent with UniProt and recent domain-mapping literature. Key regulatory phosphosites: Tyr705 (Y705) and Ser727 (S727) (STAT3β splice form lacks S727). These features match the human STAT3 literature cited below, so research proceeds on the correct target. (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18, sheikh2024acrosstalkbetween pages 18-21)

1) Key concepts and definitions
- Primary function: STAT3 is a latent cytoplasmic transcription factor that, upon activation, dimerizes and translocates to the nucleus to regulate gene expression programs controlling proliferation, survival, differentiation, angiogenesis, and immune regulation. Canonically, activation requires Y705 phosphorylation; S727 phosphorylation modulates transcriptional potency and non-canonical, especially mitochondrial, functions. (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 3-4)
- Domain structure: ND (~first 125 aa) supports cooperative DNA binding; CCD (~aa 135–315) mediates cofactor interactions; DBD (~aa 320–480) binds GAS-like elements; linker (~aa 480–575) couples to SH2; SH2 (~aa 575–680) binds phosphotyrosines for dimerization; TAD contains S727 and engages co-activators. (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18)

2) Mechanism of activation and current understanding
- Canonical IL-6–JAK–STAT3 pathway: IL-6 family cytokines engage IL-6Rα/gp130, activating associated JAKs (JAK1/2/3, TYK2). JAKs phosphorylate receptor sites and STAT3 at Y705. Reciprocal SH2–pY705 binding produces STAT3 parallel dimers that translocate to the nucleus, bind DNA via the DBD, and drive transcription; deactivation involves dephosphorylation and anti-parallel conformations. Growth factor receptors and Src-family kinases can also feed into STAT3 activation. (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 3-4, berkley2025targetingstat3for pages 4-6, sheikh2024acrosstalkbetween pages 15-18)
- Regulatory phosphorylation sites: Y705 is essential for dimerization and nuclear transcription; S727 is phosphorylated by MAPK, mTOR, and CDKs, can occur independently of Y705, enhances transcriptional output in some contexts, and is linked to mitochondrial localization and functions (mitoSTAT3). (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 3-4)
- Non-canonical roles: mitoSTAT3 binds mitochondrial DNA, associates with TFAM, modulates expression of respiratory-chain subunits, ROS, and mitochondrial biogenesis; these activities contribute to proliferation, invasiveness, and therapy resistance in cancer. Emerging interactome evidence connects mitochondrial Kv1.3 activity to STAT3 phosphorylation and a Kv1.3–STAT3–p53 signaling axis in melanoma, underscoring membrane/mitochondrial crosstalk beyond canonical cytokine signaling. (berkley2025targetingstat3for pages 4-6, berkley2025targetingstat3for pages 7-9)

3) Localization and cellular context
- Cytoplasm (latent), nucleus (active dimers bound to DNA), mitochondria (mitoSTAT3), and functional proximity to membrane/mitochondrial ion channels (e.g., Kv1.3) with implications for metabolic and apoptotic regulation. (berkley2025targetingstat3for pages 4-6, berkley2025targetingstat3for pages 7-9)

4) Transcriptional outputs and feedback regulation
- Representative direct or pathway-coupled targets: MYC, CCND1 (Cyclin D1/D2), anti-apoptotic BCL2 family members (BCL-XL, BCL2, MCL1), survivin, VEGFA, and genes associated with stemness/EMT (OCT4, SOX2, NANOG, TWIST1, Vimentin). These mediate proliferation, survival, angiogenesis, stemness, and metastasis. (berkley2025targetingstat3for pages 3-4, krajkakuzniak2024targetingstat3and pages 7-9, krajkakuzniak2024targetingstat3and pages 5-7)
- Negative feedback: SOCS proteins, especially SOCS3, are transcriptionally induced and inhibit upstream JAKs via KIR motifs and E3 ligase recruitment, closing a feedback loop that restrains STAT3 signaling; phosphatases (PTP1B, TC-PTP, SHP-1/2) also contribute. PIAS3 can restrict STAT3 transcriptional activity. (sheikh2024acrosstalkbetween pages 15-18, sheikh2024acrosstalkbetween pages 11-15, krajkakuzniak2024targetingstat3and pages 7-9)

5) Pathway placement and biochemical role
- Pathway role: STAT3 is a central nuclear effector downstream of numerous cytokines (IL-6 family), growth factors, and non-receptor tyrosine kinases, integrating inflammatory and mitogenic cues. SH2-driven dimerization and GAS-element DNA binding are core biochemical activities; S727-dependent mitochondrial functions extend STAT3’s influence on metabolism and ROS homeostasis. (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 3-4, berkley2025targetingstat3for pages 4-6)

6) Disease relevance: cancer and inflammation (recent understanding)
- Cancer: Persistent STAT3 activation is frequently observed across tumor types and drives oncogenic programs (proliferation, survival, angiogenesis, EMT, immune evasion). Dual nuclear–mitochondrial signaling via pY705 and pS727 may underlie aggressive phenotypes and therapy resistance. (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 3-4, berkley2025targetingstat3for pages 4-6)
- Inflammation and immunity: STAT3 integrates IL-6–family signals, shaping immune cell differentiation and tumor-promoting inflammation. SOCS3-mediated feedback is an important checkpoint; dysregulation of SOCS3 is implicated in inflammatory pathologies and tumor immunity. (sheikh2024acrosstalkbetween pages 15-18, sheikh2024acrosstalkbetween pages 11-15)

7) Recent developments and latest research (2023–2024 prioritized)
- Domain/mechanism refinements: 2024 analyses reaffirmed a modular STAT domain map and JAK-dependent SH2-mediated dimerization, with detailed roles for the linker and SH2 pockets relevant to inhibitor design. (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18)
- Mitochondrial and membrane crosstalk: A 2024 Science Advances BioID interactome connected Kv1.3 to STAT3 and p53, showing that mitochondrial Kv1.3 blockade increases mitochondrial ROS, decreases STAT3 phosphorylation, stabilizes p53, and reduces tumor growth/metastasis in vivo—supporting a mitoSTAT3 axis in tumor biology. (Sep 2024; https://doi.org/10.1126/sciadv.adn9361) (berkley2025targetingstat3for pages 7-9)
- Residue-specific targeting debate: Recent reviews evaluate prioritizing Y705 versus S727 or dual inhibition, noting context-dependent biology and potential toxicity tradeoffs with S727 targeting; selective pY705 inhibition remains a prevalent strategy. (Feb 2025; https://doi.org/10.3390/cancers17050755) (berkley2025targetingstat3for pages 11-13, berkley2025targetingstat3for pages 7-9, berkley2025targetingstat3for pages 1-3)

8) Current applications and real-world implementations: therapeutics and trials
- Direct STAT3 inhibitor (TTI-101, also known as C188-9): An oral, direct STAT3 inhibitor assessed in a first-in-human Phase 1 study with pharmacodynamic pY-STAT3 readouts; multiple subsequent studies launched in oncology (e.g., HCC) and fibrosis (IPF). The trial record underscores STAT3 activation across many cancers and outlines PK/PD and safety endpoints. ClinicalTrials.gov: NCT03195699 (record initiated 2017; updated thereafter). (https://clinicaltrials.gov/ct2/show/NCT03195699) (NCT03195699)
- STAT3 targeted protein degrader (KT-333): First-in-human multicenter Phase 1a/1b (dose escalation/expansion), weekly IV dosing, indications include relapsed/refractory lymphomas (PTCL, CTCL), large granular lymphocytic leukemia, T-PLL, and solid tumors. Early PD results in 2023–2024 showed robust, dose-dependent STAT3 degradation in PBMCs and dose-dependent downregulation of STAT3-regulated plasma inflammatory biomarkers (serum amyloid A, CRP), with preliminary single-agent activity (e.g., CTCL partial response) and a largely Grade 1–2 safety profile. ClinicalTrials.gov: NCT05225584; recent reviews summarize ASH updates. (https://clinicaltrials.gov/ct2/show/NCT05225584) (NCT05225584, zhong2024targetedproteindegradation pages 1-2, feng2024targetedproteindegradation pages 13-14)

9) Quantitative statistics and data from recent studies
- Prevalence: The TTI-101 Phase 1 entry notes that increased STAT3 activity occurs in approximately half of human cancers, driven by upstream cytokine/growth factor signaling or rarer STAT3 mutations (as contextualized in the record). (NCT03195699)
- Early clinical PD/efficacy (KT-333): As of July 2023, 21 patients treated at five dose levels (heterogeneous tumors: 13 solid tumors; CTCL, HL, B-cell NHL, LGLL, PTCL). PD demonstrated strong, dose-dependent, sustained STAT3 degradation and plasma biomarker suppression; preliminary efficacy with one partial response in CTCL and stable disease in three solid-tumor patients; common AEs Grade 1–2 (anemia, nausea, fatigue, constipation) with no reported DLTs at the time cited. (Aug 2024; https://doi.org/10.1186/s40364-024-00638-1) (feng2024targetedproteindegradation pages 13-14)

10) Expert opinions and analysis from authoritative sources
- Mechanistic consensus: Canonical IL-6–JAK–STAT3 with SH2-mediated dimerization and nuclear DNA binding is well established; negative feedback via SOCS3 is a central checkpoint in immune and inflammatory contexts. (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18)
- Therapeutic strategy: Given the breadth of STAT3’s oncogenic program, direct inhibition at the pY705-dependent dimer interface remains attractive; however, non-canonical mitoSTAT3 roles motivate consideration of S727 or dual-targeting, with caution regarding toxicity and context dependence. Degraders such as KT-333 provide an orthogonal, event-driven modality with early PD validation in patients. (berkley2025targetingstat3for pages 11-13, zhong2024targetedproteindegradation pages 1-2, feng2024targetedproteindegradation pages 13-14)

11) Enzyme/substrate specificity and precise role in pathways
- STAT3 is not an enzyme but a transcription factor. Biochemical action: phospho-Y705-dependent dimerization via the SH2 domain enables DNA binding to STAT consensus elements; primary function is transcriptional regulation. Substrates/ligands are DNA elements and co-regulators rather than small molecules; mitochondrial functions entail interactions with mtDNA/TFAM and respiratory components. (sheikh2024acrosstalkbetween pages 11-15, berkley2025targetingstat3for pages 4-6)

12) Evidence table of recent sources

| Source (journal/venue) | Year / Month | Focus | Key finding (1–2 sentences) | URL | Context IDs |
|---|---:|---|---|---|---|
| Berkley K., Zalejski J., Sharma A. (Cancers) | 2025 / Feb | Mechanism / Y705 vs S727, mitoSTAT3, therapeutics | Reviews canonical Y705-mediated SH2 dimerization and nuclear transcription and highlights S727-dependent mitochondrial (mitoSTAT3) functions; discusses therapeutic implications of selectively targeting Y705, S727, or both. | https://doi.org/10.3390/cancers17050755 | (berkley2025targetingstat3for pages 4-6) |
| Krajka-Kuźniak V., Belka M., Papierska K. (Cancers) | 2024 / Mar | Mechanism / SH2 dimerization, targets, regulators | Describes SH2-mediated STAT3 dimer interface and lists canonical transcriptional targets (c-MYC, CCND1, BCL-XL, VEGF) and negative regulators (SOCS, PIAS3); shows small molecules (chalcones) preventing phosphorylation, nuclear translocation and DNA binding. | https://doi.org/10.3390/cancers16061092 | (krajkakuzniak2024targetingstat3and pages 7-9, krajkakuzniak2024targetingstat3and pages 5-7) |
| Sheikh S. (arXiv) | 2024 | Domains / Activation / Feedback | Provides a STAT domain map (ND, CCD, DBD, linker, SH2, TAD), summarizes IL-6→JAK→pY705→SH2 dimerization→nuclear translocation, and documents negative feedback via SOCS proteins and phosphatases. | https://doi.org/10.53846/goediss-10532 | (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18) |
| Prosdocimi E. et al. (Science Advances) | 2024 / Sep | Interactome / non-canonical links | BioID interactome of Kv1.3 identifies a Kv1.3–STAT3–p53 signaling axis and links mitochondrial Kv1.3 activity to altered STAT3 phosphorylation and tumor phenotypes, supporting noncanonical mito-STAT3 roles. | https://doi.org/10.1126/sciadv.adn9361 | (berkley2025targetingstat3for pages 7-9) |
| ClinicalTrials.gov (TTI-101 / C188-9) — NCT03195699 | 2017 (trial start); entries/updates through 2023–2025 | Therapeutics — direct STAT3 inhibitor | TTI-101 (C188-9) is an oral, direct STAT3 inhibitor evaluated in Phase 1 with PD readouts (pY-STAT3) and multiple subsequent trials (HCC, IPF, combinations); trial record summarizes mechanism and Phase 1 objectives. | https://clinicaltrials.gov/ct2/show/NCT03195699 | (NCT03195699) |
| ClinicalTrials.gov (KT-333 STAT3 degrader) — NCT05225584 | 2022 (trial start); updates 2023–2024 | Therapeutics — STAT3 degrader (PROTAC/molecular glue) | KT-333 is a STAT3-targeting degrader tested in Phase 1 for lymphomas and solid tumors; reports at meetings and reviews note dose-dependent STAT3 degradation and early clinical evaluation. | https://clinicaltrials.gov/ct2/show/NCT05225584 | (berkley2025targetingstat3for pages 7-9, berkley2025targetingstat3for pages 1-3) |
| Zhong G. et al. (J Hematol Oncol) — ASH update on TPD | 2024 / Mar | Therapeutics — targeted protein degradation (KT-333) | ASH/meeting updates summarized clinical progression of STAT3 degraders including KT-333 and reported robust, dose-dependent STAT3 degradation in early studies, supporting TPD as a clinical modality. | https://doi.org/10.1186/s13045-024-01533-w | (berkley2025targetingstat3for pages 3-4) |
| Morelli M., Madonna S., Albanesi C. (Frontiers in Immunology) | 2024 / Jun | SOCS3 feedback / immune regulation | Reviews SOCS1/ SOCS3 as principal negative-feedback regulators of JAK/STAT signaling and highlights SOCS3 promoter regulation by STATs, with implications for restraining STAT3-driven inflammation and tumor-related signaling. | https://doi.org/10.3389/fimmu.2024.1393799 | (sheikh2024acrosstalkbetween pages 15-18) |


*Table: Concise table of recent (2023–2025) authoritative sources summarizing STAT3 domain/mechanism, noncanonical mitochondrial roles, SOCS3 feedback, and clinical therapeutic efforts (TTI-101 inhibitor, KT-333 degrader); each row includes DOI/ ClinicalTrials.gov links and context IDs for evidence tracing.*

References with URLs and dates (selection)
- Berkley K. et al. 2025-02, Cancers. Targeting STAT3: Y705 vs S727 roles; mitoSTAT3; therapeutic implications. https://doi.org/10.3390/cancers17050755 (berkley2025targetingstat3for pages 1-3, berkley2025targetingstat3for pages 4-6, berkley2025targetingstat3for pages 11-13)
- Krajka-Kuźniak V. et al. 2024-03, Cancers. STAT3/NF-κB targeting; STAT3 SH2 dimerization, transcriptional targets and regulators. https://doi.org/10.3390/cancers16061092 (krajkakuzniak2024targetingstat3and pages 7-9, krajkakuzniak2024targetingstat3and pages 5-7)
- Sheikh S. 2024, arXiv/Goettingen dissertation. STAT domain map; IL-6–JAK–STAT activation; SOCS feedback. https://doi.org/10.53846/goediss-10532 (sheikh2024acrosstalkbetween pages 11-15, sheikh2024acrosstalkbetween pages 15-18, sheikh2024acrosstalkbetween pages 18-21)
- Prosdocimi E. et al. 2024-09, Science Advances. Kv1.3–STAT3–p53 pathway; mitoKv1.3 effects on STAT3 phosphorylation and tumor phenotypes. https://doi.org/10.1126/sciadv.adn9361 (berkley2025targetingstat3for pages 7-9)
- ClinicalTrials.gov NCT03195699 (TTI-101/C188-9). Oral direct STAT3 inhibitor; Phase 1 objectives/PD. First posted 2017; updated subsequently. https://clinicaltrials.gov/ct2/show/NCT03195699 (NCT03195699)
- ClinicalTrials.gov NCT05225584 (KT-333). STAT3 degrader; Phase 1a/1b, weekly IV, lymphoma/LGLL/solid tumors. First posted 2022; updated subsequently. https://clinicaltrials.gov/ct2/show/NCT05225584 (NCT05225584)
- Zhong G. et al. 2024-03, J Hematol Oncol. TPD ASH updates; KT-333 clinical status and indications. https://doi.org/10.1186/s13045-024-01533-w (zhong2024targetedproteindegradation pages 1-2)
- Feng Y. et al. 2024-08, Biomarker Research. Clinical progression of TPD; KT-333 dose-dependent STAT3 degradation and preliminary activity. https://doi.org/10.1186/s40364-024-00638-1 (feng2024targetedproteindegradation pages 13-14)

Notes on evidence strength and limitations
- Several mechanistic details and therapeutic perspectives derive from recent reviews; where possible, trial registries and meeting-synthesis reviews were used to capture clinical status and human PD signals. While broad claims of activation prevalence appear in clinical-trial records, quantitative fractions should be interpreted cautiously and verified in tumor-type–specific datasets for precision use cases. (NCT03195699)


References

1. (sheikh2024acrosstalkbetween pages 11-15): Sana Mumtaz Sheikh. A crosstalk between nf-κb and stat1 signal transduction pathways in ischemic and proliferative diseases. ArXiv, 2024. URL: https://doi.org/10.53846/goediss-10532, doi:10.53846/goediss-10532. This article has 0 citations.

2. (sheikh2024acrosstalkbetween pages 15-18): Sana Mumtaz Sheikh. A crosstalk between nf-κb and stat1 signal transduction pathways in ischemic and proliferative diseases. ArXiv, 2024. URL: https://doi.org/10.53846/goediss-10532, doi:10.53846/goediss-10532. This article has 0 citations.

3. (sheikh2024acrosstalkbetween pages 18-21): Sana Mumtaz Sheikh. A crosstalk between nf-κb and stat1 signal transduction pathways in ischemic and proliferative diseases. ArXiv, 2024. URL: https://doi.org/10.53846/goediss-10532, doi:10.53846/goediss-10532. This article has 0 citations.

4. (berkley2025targetingstat3for pages 1-3): Kyli Berkley, Julian Zalejski, and Ashutosh Sharma. Targeting stat3 for cancer therapy: focusing on y705, s727, or dual inhibition? Cancers, 17:755, Feb 2025. URL: https://doi.org/10.3390/cancers17050755, doi:10.3390/cancers17050755. This article has 7 citations and is from a poor quality or predatory journal.

5. (berkley2025targetingstat3for pages 3-4): Kyli Berkley, Julian Zalejski, and Ashutosh Sharma. Targeting stat3 for cancer therapy: focusing on y705, s727, or dual inhibition? Cancers, 17:755, Feb 2025. URL: https://doi.org/10.3390/cancers17050755, doi:10.3390/cancers17050755. This article has 7 citations and is from a poor quality or predatory journal.

6. (berkley2025targetingstat3for pages 4-6): Kyli Berkley, Julian Zalejski, and Ashutosh Sharma. Targeting stat3 for cancer therapy: focusing on y705, s727, or dual inhibition? Cancers, 17:755, Feb 2025. URL: https://doi.org/10.3390/cancers17050755, doi:10.3390/cancers17050755. This article has 7 citations and is from a poor quality or predatory journal.

7. (berkley2025targetingstat3for pages 7-9): Kyli Berkley, Julian Zalejski, and Ashutosh Sharma. Targeting stat3 for cancer therapy: focusing on y705, s727, or dual inhibition? Cancers, 17:755, Feb 2025. URL: https://doi.org/10.3390/cancers17050755, doi:10.3390/cancers17050755. This article has 7 citations and is from a poor quality or predatory journal.

8. (krajkakuzniak2024targetingstat3and pages 7-9): Violetta Krajka-Kuźniak, Marta Belka, and Katarzyna Papierska. Targeting stat3 and nf-κb signaling pathways in cancer prevention and treatment: the role of chalcones. Cancers, 16:1092, Mar 2024. URL: https://doi.org/10.3390/cancers16061092, doi:10.3390/cancers16061092. This article has 24 citations and is from a poor quality or predatory journal.

9. (krajkakuzniak2024targetingstat3and pages 5-7): Violetta Krajka-Kuźniak, Marta Belka, and Katarzyna Papierska. Targeting stat3 and nf-κb signaling pathways in cancer prevention and treatment: the role of chalcones. Cancers, 16:1092, Mar 2024. URL: https://doi.org/10.3390/cancers16061092, doi:10.3390/cancers16061092. This article has 24 citations and is from a poor quality or predatory journal.

10. (berkley2025targetingstat3for pages 11-13): Kyli Berkley, Julian Zalejski, and Ashutosh Sharma. Targeting stat3 for cancer therapy: focusing on y705, s727, or dual inhibition? Cancers, 17:755, Feb 2025. URL: https://doi.org/10.3390/cancers17050755, doi:10.3390/cancers17050755. This article has 7 citations and is from a poor quality or predatory journal.

11. (NCT03195699):  Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers. Tvardi Therapeutics, Incorporated. 2017. ClinicalTrials.gov Identifier: NCT03195699

12. (NCT05225584):  Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors. Kymera Therapeutics, Inc.. 2022. ClinicalTrials.gov Identifier: NCT05225584

13. (zhong2024targetedproteindegradation pages 1-2): Guangcai Zhong, Ran Kong, Shi Feng, Cong Wang, Qingbo Hao, Weilin Xie, and Xiangxiang Zhou. Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ash annual meeting. Journal of Hematology & Oncology, Mar 2024. URL: https://doi.org/10.1186/s13045-024-01533-w, doi:10.1186/s13045-024-01533-w. This article has 11 citations and is from a domain leading peer-reviewed journal.

14. (feng2024targetedproteindegradation pages 13-14): Yupiao Feng, Xinting Hu, and Xin Wang. Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics. Biomarker Research, Aug 2024. URL: https://doi.org/10.1186/s40364-024-00638-1, doi:10.1186/s40364-024-00638-1. This article has 14 citations and is from a peer-reviewed journal.

## Citations

1. feng2024targetedproteindegradation pages 13-14
2. sheikh2024acrosstalkbetween pages 15-18
3. zhong2024targetedproteindegradation pages 1-2
4. sheikh2024acrosstalkbetween pages 11-15
5. sheikh2024acrosstalkbetween pages 18-21
6. https://doi.org/10.1126/sciadv.adn9361
7. https://doi.org/10.3390/cancers17050755
8. https://clinicaltrials.gov/ct2/show/NCT03195699
9. https://clinicaltrials.gov/ct2/show/NCT05225584
10. https://doi.org/10.1186/s40364-024-00638-1
11. https://doi.org/10.3390/cancers16061092
12. https://doi.org/10.53846/goediss-10532
13. https://doi.org/10.1186/s13045-024-01533-w
14. https://doi.org/10.3389/fimmu.2024.1393799
15. https://doi.org/10.53846/goediss-10532,
16. https://doi.org/10.3390/cancers17050755,
17. https://doi.org/10.3390/cancers16061092,
18. https://doi.org/10.1186/s13045-024-01533-w,
19. https://doi.org/10.1186/s40364-024-00638-1,